SEMA3C and prostate cancer: Collectively, these findings suggest that SEMA3C may be a putative driver of the cancer-promoting activities associated with FOXA1 variants, implying that the FOXA1 alterations commonly observed in clinical prostate cancer samples might mediate their oncogenic effects via SEMA3C.